Evaluation of the efficacy and safety of olopatadine and fexofenadine compared with placebo in Japanese cedar pollinosis using an environmental exposure unit

Journal of Investigational Allergology and Clinical Immunology

Volumn 19, Issue 4, 2009, Pages 299-305

  Enomoto, Tadao ^a,b   Lu, H Q ^c   Yin, M ^c   Sakoda, T ^d   Dake, Y ^e   Enomoto, K ^f   Ide, T ^g   Cheng, L ^c  

^a TOTTORI UNIVERSITY   (Japan)

^b NPO Japan Health Promotion Supporting Network   (Japan)

^c NANJING MEDICAL UNIVERSITY   (China)

^d Department of Cardiology   (Japan)

^e Dake ENT Clinic   (Japan)

^f OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^g NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Allergic rhinitis; Environmental exposure unit; Fexofenadine; H1 antihistamines; Japanese cedar pollinosis; Olopatadine; Randomized controlled trial

Indexed keywords

FEXOFENADINE; OLOPATADINE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; FEMALE; FOLLOW UP; HAY FEVER; HUMAN; JAPAN; MALE; NOSE CONGESTION; OUTCOME ASSESSMENT; POLLEN ALLERGY; RANDOMIZED CONTROLLED TRIAL; SNEEZING; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ALLERGENS; CRYPTOMERIA; DIBENZOXEPINS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; POLLEN; RHINITIS, ALLERGIC, SEASONAL; SLEEP; SNEEZING; TERFENADINE; TREATMENT OUTCOME;

EID: 68849130079     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hampel F Jr, Howland W 3rd, Van Bavel J, Ratner P. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol. 2004;14:56-63. (Pubitemid 38506432)
2. Montoro J, Sastre J, Bartra J, del Cuvillo A, Dávila I, Jáuregui I, Mullol J, Valero AL. Effect of H1 antihistamines upon the central nervous system. J Investig Allergol Clin Immunol. 2006;16 Suppl 1:24-28 (Pubitemid 46057827)
3. Enomoto T, Ide T, Ogino S. Construction of an environmental exposure unit and investigation of the effects of cetirizine hydrochloride on symptoms of cedar pollinosis in Japan. J Investig Allergol Clin Immunol. 2007;17:173-181 (Pubitemid 46890115)
4. Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol. 1996;97:617-626
5. Asaga H, Yoshida H, Baba K. Clinical efficacy of Ebastin in the treatment of cedar pollinosis in an outdoor comparative study. Arerugi. 2002;51:357-363
6. Hyo S, Fujieda S, Kawada R, Kitazawa S, Takenaka H. The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen. Ann Allergy Asthma Immunol. 2005;94:457-464 (Pubitemid 40547934)
7. Day JH, Briscoe MP, Clark RH, Ellis AK, Gervais P. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Allergy Asthma Immunol. 1997;79:163-172 (Pubitemid 27375291)
8. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: Effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol. 1998;101:638-645 (Pubitemid 28228308)
9. Berkowitz RB, Woodworth GG, Lutz C, Weiler K, Weiler J, Moss M, Meeves S. Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. Ann Allergy Asthma Immunol. 2002;89:38-45. (Pubitemid 36188066)
10. Krug N, Loedding H, Hohlfeld JM, Larbig M, Buckendahl A, Badorrek P, Geldmacher H, Behnke W, Dunkhorst W, Windt H, Luettig B, Koch W. Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis. Clin Exp Allergy. 2003;33:1667-1674 (Pubitemid 38005386)
11. Horak F, Stubner P, Zieglmeyer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airfl ow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy. 2003;58:481-485 (Pubitemid 36649307)
12. Stubner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC). Curr Med Res Opin. 2004;20:891-902. (Pubitemid 38821528)
13. Day JH, Briscoe MP, Rafeiro E, Hewlett D Jr, Chapman D, Kramer B. Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2004;25:59-68. (Pubitemid 38365570)
14. Day JH, Briscoe MP, Rafeiro E, Ratz JD, Ellis AK, Frankish CW, Chapman D, deGuia EC, Kramer B, Warner C. Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 hours postdose, in the environmental exposure unit. Allergy Asthma Proc. 2005;26:275-282
15. Xiao JZ, Kondo S, Yanagisawa N, Miyaji K, Enomoto K, Sakoda T, Iwatsuki K, Enomoto T. Clinical Efficacy of probiotic Bifi dobacterium longum for the treatment of symptoms of Japanese cedar pollen allergy in subjects evaluated in an environmental exposure unit. Allergol Int. 2007;56:67-75. (Pubitemid 46449665)
16. Morita K, Koga T, Moroi Y, Urabe K, Furue M. Rapid effects of olopatadine hydrochloride on the histamine-induced skin responses. J Dermatol. 2002;29:709-712 (Pubitemid 35416257)
17. Kamei H, Noda Y, Ishikawa K, Senzaki K, Muraoka I, Hasegawa Y, Hindmarch I, Nabeshima T. Comparative study of acute effects of single doses of fexofenadine, olopatadine, d-chlorpheniramine and placebo on psychomotor function in healthy volunteers. Hum Psychopharmacol. 2003;18:611-618 (Pubitemid 38028787)
18. Takahashi H, Ishida-Yamamoto A, Iizuka H. Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamineinduced wheal-and fl are-response, sedation, and psychomotor performance. Clin Exp Dermatol. 2004;29:526-532 (Pubitemid 39278201)
19. Takahashi H, Zhang Y, Morita E. Evaluation of the antihistamine effects of olopatadine, cetirizine and fexofenadine during a 24 h period: a double-blind, randomized, crossover, placebocontrolled comparison in skin responses induced by histamine iontophoresis. Arch Dermatol Res. 2008;300:291-295
20. Ratner PH, Hampel FC, Amar NJ, van Bavel JH, Mohar D, Marple BF, Roland PS, Wall GM, Brubaker MJ, Drake M, Turner D, Silver LH. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. Ann Allergy Asthma Immunol. 2005;95:474-479 (Pubitemid 41688510)
21. Meltzer EO, Hampel FC, Ratner PH, Bernstein DI, Larsen LV, Berger WE, Finn AF Jr, Marple BF, Roland PS, Wall GM, Brubaker MJ, Dimas C, Potts SL, Silver LH, Barnes JR. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2005;95:600-606 (Pubitemid 43010489)
22. Hampel FC Jr, Ratner PH, Amar NJ, van Bavel JH, Mohar D, Fairchild CJ, Wall GM, Brubaker MJ, Drake M, Crenshaw KM. Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo. Allergy Asthma Proc. 2006;27:202-207 (Pubitemid 44153865)
23. Patel D, Garadi R, Brubaker M, Conroy JP, Kaji Y, Crenshaw K, Whitling A, Wall GM. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc. 2007;28:592-599
24. Patel P, Roland PS, Marple BF, Benninger PJ, Margalias H, Brubaker M, Beezley SF, Drake M, Potts SL, Wall GM. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg. 2007;137:918-924 (Pubitemid 350117069)
25. Hatta T, Masui T, Ito Y, Ito E, Hasegawa Y, Matsuyama Y. Relation between the prefrontal cortex and cerebro-cerebellar functions: evidence from the results of stabilometrical indexes. Appl Neuropsychol. 2004;11:153-160 (Pubitemid 39658447)
26. Day JH, Horak F, Briscoe MP, Canonica GW, Fineman SM, Krug N, Leynadier F, Lieberman P, Quirce S, Takenaka H, Van Cauwenberge P. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Rev. 2006;6:31-59.
27. Yamagiwa M. Immediate effect of olopatadine hydrochloride (Allelock®) on allergic nasal obstruction. J New Rem & Clin. 2002;51:131-136
28. Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002;88:379-397 (Pubitemid 34516564)
29. Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y. Properties of olopatadine hydrochloride, a new antiallergic/ antihistaminic drug. Arzneimittelforschung. 2004;54:809-829 (Pubitemid 39657678)